title: Indications for mycophenolate mofetil therapy in hepatitis C-patients undergoing liver transplantation.
authors.affiliation: Department of Surgery, Virchow Clinic, Humboldt University, Berlin, Germany.
authors.forename: K P
authors.initials: KP
authors.lastname: Platz
authors.forename: A R
authors.initials: AR
authors.lastname: Mueller
authors.forename: C
authors.initials: C
authors.lastname: Willimski
authors.forename: B
authors.initials: B
authors.lastname: Mansoorian
authors.forename: T
authors.initials: T
authors.lastname: Berg
authors.forename: R
authors.initials: R
authors.lastname: Neuhaus
authors.forename: U
authors.initials: U
authors.lastname: Hopf
authors.forename: H
authors.initials: H
authors.lastname: Lobeck
authors.forename: P
authors.initials: P
authors.lastname: Neuhaus
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D006084:Graft Rejection / Q000188:drug therapy*; D006526:Hepatitis C / Q000150:complications / Q000503:physiopathology / Q000601:surgery*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008103:Liver Cirrhosis / Q000209:etiology / Q000601:surgery*; D016031:Liver Transplantation / Q000276:immunology* / Q000401:mortality; D008775:Methylprednisolone / Q000627:therapeutic use; D016853:Muromonab-CD3 / Q000627:therapeutic use; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015375:Receptors, Interleukin-2 / Q000276:immunology; D012008:Recurrence; D012086:Reoperation; D012189:Retrospective Studies; D015996:Survival Rate; D016559:Tacrolimus / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D015375:Receptors, Interleukin-2; D016572:Cyclosporine; C079843:inolimomab; D009173:Mycophenolic Acid; D016559:Tacrolimus; D008775:Methylprednisolone